PHIO PHARMACEUTICALS CORPORATION (consolidare)

Phio Pharmaceuticals Corp. (https://phiopharma.com/) is a biotechnology company. The Company is focused on developing immuno-oncology therapeutics based on its self-delivering ribonucleic acid interface (RNAi) INTASYL therapeutic platform. The Company has developed a product platform based on its INTASYL technology that allows selective non-genetically modified programming of adoptive cell therapy (ACT) cells and of the tumor micro-environment (TME), resulting in reduced immune inhibition and in improved immunotherapy. Its lead product candidate, PH-762, is an INTASYL compound that targets the checkpoint protein PD-1, which acts as a type of switch that prevents T cells from attacking certain cells, such as cancer cells, in the body. Its second product candidate, PH-894, is an INTASYL compound that targets BRD4, which is a regulator of gene expression impacting cell differentiation. It is also developing PH-804, which targets the suppressive immune receptor TIGIT.

• PHIO PHARMACEUTICALS CORPORATION (consolidare)